drugset / Trial / NCT06430645

Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia

NCT06430645

Recruiting 150 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupTriple-blindBasic science

Summary

Esketamine is an antagonist of N-methyl-d-aspartate (NMDA) receptor different from other gamma-aminobutyric acid (GABA) receptor agonists. Recent studies showed that subanesthetic doses of ketamine not only deepen anesthesia but also accelerate recovery from isoflurane anesthesia in mice. It is necessary to verify if it applies to human. Besides inducing behavioral unresponsiveness, an optimal and important goal of general anesthesia is to prevent connected consciousness. The results of many studies support the conclusion that anesthesia-related unconsciousness is a consistent functional disconnection of lateral frontoparietal networks.The goal of this clinical trial is to learn if subanaesthetic doses of esketamine works to accelerate the recovery of consciousness from propofol anesthesia. It will also learn about the change of brain network when administrated the esketamine during propofol anesthesia. The main questions it aims to answer are: 1. Does subanaesthetic doses of esketamine can accelerate recovery from propofol anaesthesia? 2. What will happen to brain network connection after different doses of esketamine during propofol anesthesia?

Timeline

Start
2024-05-05
Primary completion
2024-10-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.3 mg/kg Intravenous
Subject Esketamine Other / unclassified 0.6 mg/kg Intravenous

Indications

No indication recorded.